Floatz logo

Cediranib

Lymphangioleiomyomatosis

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Lymphangioleiomyomatosis cohort.

Asset / SponsorPhaseRating
Rapamycin
University of Cincinnati
Phase 2BB
Everolimus
University of Cincinnati
Phase 3BB
Doxycycline
University of Nottingham
Phase 4BB
SIMVASTATIN
University of Pennsylvania
Phase 1/2CCC
ACETIC ACID, SODIUM SALT (1:1)
Brigham and Women's Hospital
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →